You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNintedanib
Accession NumberDB09079
TypeSmall Molecule
GroupsApproved
DescriptionNintedanib is a drug indicated for the treatment of idiopathic pulmonary fibrosis (IPF) that targets multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology. In addition, nintedanib inhibits the following nRTKs: Lck, Lyn and Src kinases. The contribution of FLT3 and nRTK inhibition to IPF efficacy is unknown. Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease characterized by a progressive loss of lung function with worsening dyspnoea and cough. Development is thought to be instigated by repetitive lung injury (such as by cigarette smoke, industrial dusts, gastrooesophageal reflux and viral infection) leading to destruction of epithelial alveolar cells. Subsequent dysregulation of the repair process results in the proliferation/migration of fibroblasts and their differentiation into myofibroblasts, abnormal extracellular matrix deposition and excessive collagen accumulation in the lung interstitium and alveolar space, leading to progressive fibrosis and stiffening of the lungs. Vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) mediate various processes, including fibrogenesis and angiogenesis, and are implicated in the pathogenesis of IPF. By blocking substrate binding and downstream signalling cascades, nintedanib interferes with processes active in fibrosis such as fibroblast proliferation, migration and differentiation, and the secretion of extracellular matrix.
Structure
Thumb
Synonyms
methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate
External Identifiers
  • BIBF 1120
  • BIBF-1120
  • BIBF1120
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ofevcapsule100 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2014-10-28Not applicableUs
Ofevcapsule150 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2014-10-28Not applicableUs
Ofevcapsule100 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2015-06-29Not applicableCanada
Ofevcapsule150 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2015-06-29Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
VargatefBoehringer-Ingelheim
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nintedanib Esylate
ThumbNot applicableDBSALT001111
Categories
UNIIG6HRD2P839
CAS number656247-17-5
WeightAverage: 539.6248
Monoisotopic: 539.253254569
Chemical FormulaC31H33N5O4
InChI KeyXZXHXSATPCNXJR-ZIADKAODSA-N
InChI
InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-
IUPAC Name
methyl (3Z)-2-hydroxy-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-3H-indole-6-carboxylate
SMILES
COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indolecarboxylic acids. These are compounds containing a carboxylic acid group linked to an indole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndolecarboxylic acids and derivatives
Direct ParentIndolecarboxylic acids
Alternative Parents
Substituents
  • Indolecarboxylic acid
  • N-piperazineacetamide
  • Alpha-amino acid or derivatives
  • Dihydroindole
  • Benzylether
  • Substituted aniline
  • Benzoyl
  • N-alkylpiperazine
  • N-methylpiperazine
  • Aniline
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Methyl ester
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Enamine
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
PharmacodynamicsBy competitively and reversibly inhibiting the adenosine triphosphate binding pocket of the receptor tyrosine kinases VEGFR, FGFR and PDGFR, nintedanib blocks the intracellular signalling needed for the proliferation, migration and transformation of fibroblasts.
Mechanism of actionNintedanib is a small molecule that targets multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology. In addition, nintedanib inhibits the following nRTKs: Lck, Lyn and Src kinases. The contribution of FLT3 and nRTK inhibition to IPF efficacy is unknown.
Related Articles
AbsorptionNintedanib reaches maximum plasma concentrations approximately 2 to 4 hours after administration, and absolute bioavailability is 4.7%.
Volume of distribution

1050 L

Protein bindingThe in vitro protein binding of nintedanib in human plasma was high, with a bound fraction of 97.8%. Serum albumin is considered to be the major binding protein.
Metabolism

The prevalent metabolic reaction for nintedanib is hydrolytic cleavage by esterases resulting in the free acid moiety BIBF 1202. BIBF 1202 is subsequently glucuronidated by UGT enzymes, namely UGT 1A1, UGT 1A7, UGT 1A8, and UGT 1A10 to BIBF 1202 glucuronide. Only a minor extent of the biotransformation of nintedanib consisted of CYP pathways, with CYP 3A4 being the predominant enzyme involved. In vitro, CYP-dependent metabolism accounted for about 5% compared to about 25% ester cleavage.

SubstrateEnzymesProduct
Nintedanib
Not Available
BIBF 1202Details
BIBF 1202
BIBF 1202 glucuronideDetails
Route of eliminationThe major route of elimination of drug-related radioactivity after oral administration of [14C] nintedanib was via fecal/biliary excretion (93.4% of dose), and the majority was excreted as BIBF 1202. The contribution of renal excretion to the total clearance was low (0.65% of dose). The overall recovery was considered complete (above 90%) within 4 days after dosing.
Half life9.5 hours
Clearance

Total plasma clearance after intravenous infusion was found to be 1390 mL/min, while renal clearance was found to be 20 mL/min.

ToxicityThe most common adverse reactions (>5%) reported during clinical trials include diarrhea, nausea, vomiting, abdominal pain, liver enzyme elevation, headache, decreased weight, decreased appetite, and hypertension. The most frequent serious adverse reactions reported in patients treated with nintedanib, more than placebo, were bronchitis (1.2% vs. 0.8%) and myocardial infarction (1.5% vs. 0.4%). The most common adverse events leading to death in patients treated with nintedanib, more than placebo, were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). Nintedanib can also cause fetal harm when administered to a pregnant woman: if it is used during pregnancy, or if the patient becomes pregnant while taking nintedanib, the patient should be apprised of the potential hazard to a fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral100 mg/1
Capsuleoral100 mg
Capsuleoral150 mg
Capsuleoral150 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6762180 No2000-12-102020-12-10Us
US7119093 No2004-02-212024-02-21Us
US7989474 No2004-04-062024-04-06Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0398 mg/mLALOGPS
logP3.29ALOGPS
logP2.4ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)-6.1ChemAxon
pKa (Strongest Basic)15ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area97.71 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity159.85 m3·mol-1ChemAxon
Polarizability59.7 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Keating GM: Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis. Drugs. 2015 Jul;75(10):1131-40. doi: 10.1007/s40265-015-0418-6. [PubMed:26063212 ]
  2. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
  3. Mazzei ME, Richeldi L, Collard HR: Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2015 Jun;9(3):121-9. doi: 10.1177/1753465815579365. Epub 2015 Apr 10. [PubMed:25862013 ]
  4. Stopfer P, Rathgen K, Bischoff D, Ludtke S, Marzin K, Kaiser R, Wagner K, Ebner T: Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011 Apr;41(4):297-311. doi: 10.3109/00498254.2010.545452. Epub 2011 Jan 4. [PubMed:21204634 ]
External Links
ATC CodesL01XE31
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (484 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Nintedanib.
AcenocoumarolThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Nintedanib.
AcetaminophenThe serum concentration of Nintedanib can be decreased when it is combined with Acetaminophen.
AcetazolamideThe serum concentration of Nintedanib can be increased when it is combined with Acetazolamide.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Nintedanib.
AfatinibThe serum concentration of Nintedanib can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Nintedanib can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Nintedanib can be decreased when it is combined with Alclometasone.
AldesleukinThe serum concentration of Nintedanib can be increased when it is combined with Aldesleukin.
AldosteroneThe serum concentration of Nintedanib can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Nintedanib can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Nintedanib can be increased when it is combined with Alfentanil.
AlimemazineThe serum concentration of Nintedanib can be decreased when it is combined with Alimemazine.
AmantadineThe serum concentration of Nintedanib can be increased when it is combined with Amantadine.
AmbroxolThe serum concentration of Nintedanib can be increased when it is combined with Ambroxol.
AminoglutethimideThe serum concentration of Nintedanib can be decreased when it is combined with Aminoglutethimide.
Aminohippuric acidThe serum concentration of Nintedanib can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Nintedanib can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Nintedanib can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Nintedanib can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Nintedanib can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Nintedanib can be increased when it is combined with Amsacrine.
AnastrozoleThe serum concentration of Nintedanib can be increased when it is combined with Anastrozole.
AncrodThe risk or severity of adverse effects can be increased when Ancrod is combined with Nintedanib.
AntipyrineThe serum concentration of Nintedanib can be increased when it is combined with Antipyrine.
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Nintedanib.
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Nintedanib.
AprepitantThe serum concentration of Nintedanib can be increased when it is combined with Aprepitant.
ArdeparinThe risk or severity of adverse effects can be increased when Ardeparin is combined with Nintedanib.
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Nintedanib.
ArmodafinilThe serum concentration of Nintedanib can be decreased when it is combined with Armodafinil.
Arsenic trioxideThe serum concentration of Nintedanib can be increased when it is combined with Arsenic trioxide.
ArtemetherThe serum concentration of Nintedanib can be decreased when it is combined with Artemether.
AstemizoleThe serum concentration of Nintedanib can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Nintedanib can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Nintedanib can be increased when it is combined with Atenolol.
AtomoxetineThe serum concentration of Nintedanib can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Nintedanib can be decreased when it is combined with Atorvastatin.
AzatadineThe serum concentration of Nintedanib can be decreased when it is combined with Azatadine.
AzelastineThe serum concentration of Nintedanib can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Nintedanib can be increased when it is combined with Azithromycin.
BecaplerminThe risk or severity of adverse effects can be increased when Becaplermin is combined with Nintedanib.
BenzocaineThe serum concentration of Nintedanib can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Nintedanib can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Nintedanib can be increased when it is combined with Betamethasone.
BevacizumabBevacizumab may increase the cardiotoxic activities of Nintedanib.
BexaroteneThe serum concentration of Nintedanib can be decreased when it is combined with Bexarotene.
BicalutamideThe serum concentration of Nintedanib can be increased when it is combined with Bicalutamide.
BifonazoleThe serum concentration of Nintedanib can be increased when it is combined with Bifonazole.
BiperidenThe serum concentration of Nintedanib can be increased when it is combined with Biperiden.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Nintedanib.
BoceprevirThe serum concentration of Nintedanib can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Nintedanib can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Nintedanib can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Nintedanib can be increased when it is combined with Bosutinib.
Brentuximab vedotinThe serum concentration of Nintedanib can be increased when it is combined with Brentuximab vedotin.
BromocriptineThe serum concentration of Nintedanib can be increased when it is combined with Bromocriptine.
BuprenorphineThe serum concentration of Nintedanib can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Nintedanib can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Nintedanib can be increased when it is combined with Cabazitaxel.
CabergolineThe serum concentration of Nintedanib can be increased when it is combined with Cabergoline.
CaffeineThe serum concentration of Nintedanib can be increased when it is combined with Caffeine.
CalcitriolThe serum concentration of Nintedanib can be decreased when it is combined with Calcitriol.
CanagliflozinThe serum concentration of Nintedanib can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Nintedanib can be increased when it is combined with Candesartan.
CapsaicinThe serum concentration of Nintedanib can be increased when it is combined with Capsaicin.
CaptoprilThe serum concentration of Nintedanib can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Nintedanib can be decreased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Nintedanib can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Nintedanib can be increased when it is combined with Caspofungin.
CefradineThe serum concentration of Nintedanib can be decreased when it is combined with Cefradine.
CerivastatinThe serum concentration of Nintedanib can be decreased when it is combined with Cerivastatin.
CertoparinThe risk or severity of adverse effects can be increased when Certoparin is combined with Nintedanib.
ChloramphenicolThe serum concentration of Nintedanib can be increased when it is combined with Chloramphenicol.
ChloroquineThe serum concentration of Nintedanib can be increased when it is combined with Chloroquine.
ChlorphenesinThe serum concentration of Nintedanib can be decreased when it is combined with Chlorphenesin.
ChlorpromazineThe serum concentration of Nintedanib can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Nintedanib can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Nintedanib can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe serum concentration of Nintedanib can be increased when it is combined with Chlorzoxazone.
CholesterolThe serum concentration of Nintedanib can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Nintedanib can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Nintedanib can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Nintedanib can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Nintedanib can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Nintedanib can be increased when it is combined with Cisapride.
CitalopramThe serum concentration of Nintedanib can be increased when it is combined with Citalopram.
Citric AcidThe risk or severity of adverse effects can be increased when Citric Acid is combined with Nintedanib.
ClarithromycinThe serum concentration of Nintedanib can be decreased when it is combined with Clarithromycin.
ClemastineThe serum concentration of Nintedanib can be increased when it is combined with Clemastine.
ClevidipineThe serum concentration of Nintedanib can be decreased when it is combined with Clevidipine.
ClindamycinThe serum concentration of Nintedanib can be increased when it is combined with Clindamycin.
ClofazimineThe serum concentration of Nintedanib can be increased when it is combined with Clofazimine.
ClofibrateThe serum concentration of Nintedanib can be decreased when it is combined with Clofibrate.
ClomifeneThe serum concentration of Nintedanib can be increased when it is combined with Clomifene.
ClomipramineThe serum concentration of Nintedanib can be increased when it is combined with Clomipramine.
ClotiazepamThe serum concentration of Nintedanib can be increased when it is combined with Clotiazepam.
ClotrimazoleThe serum concentration of Nintedanib can be decreased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Nintedanib can be decreased when it is combined with Clozapine.
CobicistatThe serum concentration of Nintedanib can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of Nintedanib can be increased when it is combined with Cocaine.
ColchicineThe serum concentration of Nintedanib can be decreased when it is combined with Colchicine.
ColforsinThe serum concentration of Nintedanib can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Nintedanib can be increased when it is combined with Conivaptan.
Cortisone acetateThe serum concentration of Nintedanib can be increased when it is combined with Cortisone acetate.
CrizotinibThe serum concentration of Nintedanib can be increased when it is combined with Crizotinib.
CyclophosphamideThe serum concentration of Nintedanib can be decreased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Nintedanib can be decreased when it is combined with Cyclosporine.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Nintedanib.
DabrafenibThe serum concentration of Nintedanib can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Nintedanib can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Nintedanib can be increased when it is combined with Dactinomycin.
DalfopristinThe serum concentration of Nintedanib can be increased when it is combined with Dalfopristin.
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Nintedanib.
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Nintedanib.
DanazolThe serum concentration of Nintedanib can be increased when it is combined with Danazol.
DarunavirThe serum concentration of Nintedanib can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Nintedanib can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Nintedanib can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Nintedanib can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Nintedanib can be increased when it is combined with Delavirdine.
DesipramineThe serum concentration of Nintedanib can be increased when it is combined with Desipramine.
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Nintedanib.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Nintedanib.
DesloratadineThe serum concentration of Nintedanib can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Nintedanib can be decreased when it is combined with Dexamethasone.
DextranThe risk or severity of adverse effects can be increased when Dextran is combined with Nintedanib.
Dextran 40The risk or severity of adverse effects can be increased when Dextran 40 is combined with Nintedanib.
Dextran 70The risk or severity of adverse effects can be increased when Dextran 70 is combined with Nintedanib.
Dextran 75The risk or severity of adverse effects can be increased when Dextran 75 is combined with Nintedanib.
DextromethorphanThe serum concentration of Nintedanib can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe serum concentration of Nintedanib can be increased when it is combined with Dextropropoxyphene.
DiazepamThe serum concentration of Nintedanib can be increased when it is combined with Diazepam.
DiclofenacThe serum concentration of Nintedanib can be increased when it is combined with Diclofenac.
DicloxacillinThe serum concentration of Nintedanib can be decreased when it is combined with Dicloxacillin.
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Nintedanib.
DiethylstilbestrolThe serum concentration of Nintedanib can be increased when it is combined with Diethylstilbestrol.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Nintedanib.
DigoxinThe serum concentration of Nintedanib can be decreased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Nintedanib can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Nintedanib can be increased when it is combined with Diltiazem.
Dimethyl sulfoxideThe serum concentration of Nintedanib can be increased when it is combined with Dimethyl sulfoxide.
DipyridamoleThe serum concentration of Nintedanib can be increased when it is combined with Dipyridamole.
DocetaxelThe serum concentration of Nintedanib can be increased when it is combined with Docetaxel.
DoxazosinThe serum concentration of Nintedanib can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Nintedanib can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Nintedanib can be decreased when it is combined with Doxorubicin.
DoxycyclineThe serum concentration of Nintedanib can be increased when it is combined with Doxycycline.
DronabinolThe serum concentration of Nintedanib can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Nintedanib can be increased when it is combined with Dronedarone.
EconazoleThe serum concentration of Nintedanib can be increased when it is combined with Econazole.
Edetic AcidThe risk or severity of adverse effects can be increased when Edetic Acid is combined with Nintedanib.
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Nintedanib.
EfavirenzThe serum concentration of Nintedanib can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Nintedanib can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Nintedanib can be decreased when it is combined with Eletriptan.
EnalaprilThe serum concentration of Nintedanib can be increased when it is combined with Enalapril.
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Nintedanib.
EnzalutamideThe serum concentration of Nintedanib can be decreased when it is combined with Enzalutamide.
EpinephrineThe serum concentration of Nintedanib can be increased when it is combined with Epinephrine.
Ergoloid mesylateThe serum concentration of Nintedanib can be increased when it is combined with Ergoloid mesylate.
ErgonovineThe serum concentration of Nintedanib can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Nintedanib can be increased when it is combined with Ergotamine.
ErythromycinThe serum concentration of Nintedanib can be increased when it is combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Nintedanib can be decreased when it is combined with Eslicarbazepine acetate.
EstramustineThe serum concentration of Nintedanib can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Nintedanib can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Nintedanib can be decreased when it is combined with Estrone.
EthanolThe serum concentration of Nintedanib can be decreased when it is combined with Ethanol.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Nintedanib.
EtoposideThe serum concentration of Nintedanib can be decreased when it is combined with Etoposide.
EtoricoxibThe serum concentration of Nintedanib can be increased when it is combined with Etoricoxib.
EtravirineThe serum concentration of Nintedanib can be decreased when it is combined with Etravirine.
EzetimibeThe serum concentration of Nintedanib can be increased when it is combined with Ezetimibe.
FelbamateThe serum concentration of Nintedanib can be decreased when it is combined with Felbamate.
FelodipineThe serum concentration of Nintedanib can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Nintedanib can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Nintedanib can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Nintedanib can be increased when it is combined with Fidaxomicin.
FlucloxacillinThe serum concentration of Nintedanib can be decreased when it is combined with Flucloxacillin.
FluconazoleThe serum concentration of Nintedanib can be increased when it is combined with Fluconazole.
FluorometholoneThe serum concentration of Nintedanib can be decreased when it is combined with Fluorometholone.
FluoxetineThe serum concentration of Nintedanib can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Nintedanib can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Nintedanib can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Nintedanib can be increased when it is combined with Flurazepam.
Fluticasone PropionateThe serum concentration of Nintedanib can be increased when it is combined with Fluticasone Propionate.
FluvastatinThe serum concentration of Nintedanib can be decreased when it is combined with Fluvastatin.
FluvoxamineThe serum concentration of Nintedanib can be increased when it is combined with Fluvoxamine.
Fondaparinux sodiumThe risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Nintedanib.
FosamprenavirThe serum concentration of Nintedanib can be increased when it is combined with Fosamprenavir.
FosphenytoinThe serum concentration of Nintedanib can be decreased when it is combined with Fosphenytoin.
GefitinibThe serum concentration of Nintedanib can be increased when it is combined with Gefitinib.
GemfibrozilThe serum concentration of Nintedanib can be decreased when it is combined with Gemfibrozil.
GenisteinThe serum concentration of Nintedanib can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Nintedanib can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Nintedanib can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Nintedanib can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Nintedanib can be increased when it is combined with Grepafloxacin.
GriseofulvinThe serum concentration of Nintedanib can be decreased when it is combined with Griseofulvin.
GuanethidineThe serum concentration of Nintedanib can be decreased when it is combined with Guanethidine.
HaloperidolThe serum concentration of Nintedanib can be increased when it is combined with Haloperidol.
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Nintedanib.
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Nintedanib.
Histamine PhosphateThe serum concentration of Nintedanib can be increased when it is combined with Histamine Phosphate.
HydralazineThe serum concentration of Nintedanib can be increased when it is combined with Hydralazine.
HydrocortamateThe serum concentration of Nintedanib can be decreased when it is combined with Hydrocortamate.
HydrocortisoneThe serum concentration of Nintedanib can be increased when it is combined with Hydrocortisone.
IdelalisibThe serum concentration of Nintedanib can be decreased when it is combined with Idelalisib.
IfosfamideThe serum concentration of Nintedanib can be decreased when it is combined with Ifosfamide.
ImatinibThe serum concentration of Nintedanib can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Nintedanib can be increased when it is combined with Imipramine.
IndinavirThe serum concentration of Nintedanib can be decreased when it is combined with Indinavir.
indisulamThe serum concentration of Nintedanib can be increased when it is combined with indisulam.
IndomethacinThe serum concentration of Nintedanib can be increased when it is combined with Indomethacin.
IrbesartanThe serum concentration of Nintedanib can be increased when it is combined with Irbesartan.
IrinotecanThe serum concentration of Nintedanib can be increased when it is combined with Irinotecan.
IsavuconazoniumThe serum concentration of Nintedanib can be increased when it is combined with Isavuconazonium.
IsoniazidThe serum concentration of Nintedanib can be increased when it is combined with Isoniazid.
IsradipineThe serum concentration of Nintedanib can be increased when it is combined with Isradipine.
ItraconazoleThe serum concentration of Nintedanib can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Nintedanib can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Nintedanib can be increased when it is combined with Ivermectin.
JosamycinThe serum concentration of Nintedanib can be increased when it is combined with Josamycin.
KetamineThe serum concentration of Nintedanib can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Nintedanib can be increased when it is combined with Ketazolam.
KetoconazoleThe serum concentration of Nintedanib can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Nintedanib can be decreased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Nintedanib can be increased when it is combined with Lapatinib.
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Nintedanib.
LercanidipineThe serum concentration of Nintedanib can be increased when it is combined with Lercanidipine.
LevofloxacinThe serum concentration of Nintedanib can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Nintedanib can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Nintedanib can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Nintedanib can be increased when it is combined with Linagliptin.
LiothyronineThe serum concentration of Nintedanib can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Nintedanib can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Nintedanib can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Nintedanib can be increased when it is combined with Lomitapide.
LomustineThe serum concentration of Nintedanib can be increased when it is combined with Lomustine.
LoperamideThe serum concentration of Nintedanib can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Nintedanib can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Nintedanib can be decreased when it is combined with Loratadine.
LosartanThe serum concentration of Nintedanib can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Nintedanib can be increased when it is combined with Lovastatin.
LuliconazoleThe serum concentration of Nintedanib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Nintedanib can be decreased when it is combined with Lumacaftor.
MaprotilineThe serum concentration of Nintedanib can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Nintedanib can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe serum concentration of Nintedanib can be decreased when it is combined with Medroxyprogesterone acetate.
MefloquineThe serum concentration of Nintedanib can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Nintedanib can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Nintedanib can be increased when it is combined with Meprobamate.
MequitazineThe serum concentration of Nintedanib can be increased when it is combined with Mequitazine.
MetamizoleThe serum concentration of Nintedanib can be decreased when it is combined with Metamizole.
MethadoneThe serum concentration of Nintedanib can be decreased when it is combined with Methadone.
MethazolamideThe serum concentration of Nintedanib can be increased when it is combined with Methazolamide.
MethimazoleThe serum concentration of Nintedanib can be increased when it is combined with Methimazole.
MethylergometrineThe serum concentration of Nintedanib can be increased when it is combined with Methylergometrine.
MethylprednisoloneThe serum concentration of Nintedanib can be increased when it is combined with Methylprednisolone.
MetoprololThe serum concentration of Nintedanib can be increased when it is combined with Metoprolol.
MetronidazoleThe serum concentration of Nintedanib can be increased when it is combined with Metronidazole.
MetyraponeThe serum concentration of Nintedanib can be decreased when it is combined with Metyrapone.
MibefradilThe serum concentration of Nintedanib can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Nintedanib can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Nintedanib can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Nintedanib can be decreased when it is combined with Mifepristone.
MirtazapineThe serum concentration of Nintedanib can be increased when it is combined with Mirtazapine.
MitomycinThe serum concentration of Nintedanib can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Nintedanib can be decreased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Nintedanib can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Nintedanib can be increased when it is combined with Morphine.
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Nintedanib.
NafcillinThe serum concentration of Nintedanib can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Nintedanib can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Nintedanib can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Nintedanib can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Nintedanib can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Nintedanib can be increased when it is combined with Neostigmine.
NevirapineThe serum concentration of Nintedanib can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Nintedanib can be decreased when it is combined with Nicardipine.
NicotinamideThe serum concentration of Nintedanib can be increased when it is combined with Nicotinamide.
NifedipineThe serum concentration of Nintedanib can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Nintedanib can be increased when it is combined with Nilotinib.
NilvadipineThe serum concentration of Nintedanib can be increased when it is combined with Nilvadipine.
NisoldipineThe serum concentration of Nintedanib can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Nintedanib can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Nintedanib can be increased when it is combined with Nitrendipine.
Nitric OxideThe serum concentration of Nintedanib can be increased when it is combined with Nitric Oxide.
NorethisteroneThe serum concentration of Nintedanib can be decreased when it is combined with Norethisterone.
NorfloxacinThe serum concentration of Nintedanib can be increased when it is combined with Norfloxacin.
NoscapineThe serum concentration of Nintedanib can be increased when it is combined with Noscapine.
OlanzapineThe serum concentration of Nintedanib can be increased when it is combined with Olanzapine.
OlaparibThe serum concentration of Nintedanib can be increased when it is combined with Olaparib.
OmeprazoleThe serum concentration of Nintedanib can be decreased when it is combined with Omeprazole.
OrlistatThe serum concentration of Nintedanib can be decreased when it is combined with Orlistat.
OsimertinibThe serum concentration of Nintedanib can be decreased when it is combined with Osimertinib.
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Nintedanib.
OuabainOuabain may decrease the cardiotoxic activities of Nintedanib.
OxcarbazepineThe serum concentration of Nintedanib can be decreased when it is combined with Oxcarbazepine.
OxiconazoleThe serum concentration of Nintedanib can be decreased when it is combined with Oxiconazole.
OxybutyninThe serum concentration of Nintedanib can be increased when it is combined with Oxybutynin.
P-NitrophenolThe serum concentration of Nintedanib can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Nintedanib can be decreased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Nintedanib can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Nintedanib can be decreased when it is combined with Pantoprazole.
ParamethasoneThe serum concentration of Nintedanib can be increased when it is combined with Paramethasone.
ParoxetineThe serum concentration of Nintedanib can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Nintedanib can be increased when it is combined with Pazopanib.
PegvisomantThe serum concentration of Nintedanib can be decreased when it is combined with Pegvisomant.
PentobarbitalThe serum concentration of Nintedanib can be decreased when it is combined with Pentobarbital.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nintedanib.
PerampanelThe serum concentration of Nintedanib can be decreased when it is combined with Perampanel.
PergolideThe serum concentration of Nintedanib can be increased when it is combined with Pergolide.
PerindoprilThe serum concentration of Nintedanib can be increased when it is combined with Perindopril.
PhenelzineThe serum concentration of Nintedanib can be increased when it is combined with Phenelzine.
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Nintedanib.
PhenobarbitalThe serum concentration of Nintedanib can be decreased when it is combined with Phenobarbital.
PhenprocoumonThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Nintedanib.
PhenylbutazoneThe serum concentration of Nintedanib can be decreased when it is combined with Phenylbutazone.
PhenytoinThe serum concentration of Nintedanib can be decreased when it is combined with Phenytoin.
PilocarpineThe serum concentration of Nintedanib can be increased when it is combined with Pilocarpine.
PimozideThe serum concentration of Nintedanib can be increased when it is combined with Pimozide.
PioglitazoneThe serum concentration of Nintedanib can be decreased when it is combined with Pioglitazone.
PirfenidoneThe serum concentration of Nintedanib can be decreased when it is combined with Pirfenidone.
Platelet Activating FactorThe serum concentration of Nintedanib can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Nintedanib can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Nintedanib can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Nintedanib can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Nintedanib can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Nintedanib can be increased when it is combined with Prednisolone.
PrednisoneThe serum concentration of Nintedanib can be decreased when it is combined with Prednisone.
PrimaquineThe serum concentration of Nintedanib can be increased when it is combined with Primaquine.
PrimidoneThe serum concentration of Nintedanib can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Nintedanib can be decreased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Nintedanib can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Nintedanib can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Nintedanib can be increased when it is combined with Propafenone.
PropofolThe serum concentration of Nintedanib can be increased when it is combined with Propofol.
PropranololThe serum concentration of Nintedanib can be increased when it is combined with Propranolol.
Protein CThe risk or severity of adverse effects can be increased when Protein C is combined with Nintedanib.
ProtocatechualdehydeThe risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Nintedanib.
ProtriptylineThe serum concentration of Nintedanib can be increased when it is combined with Protriptyline.
PyridostigmineThe serum concentration of Nintedanib can be decreased when it is combined with Pyridostigmine.
QuercetinThe serum concentration of Nintedanib can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Nintedanib can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Nintedanib can be decreased when it is combined with Quinidine.
QuinineThe serum concentration of Nintedanib can be decreased when it is combined with Quinine.
QuinupristinThe serum concentration of Nintedanib can be increased when it is combined with Quinupristin.
RabeprazoleThe serum concentration of Nintedanib can be increased when it is combined with Rabeprazole.
RaloxifeneThe serum concentration of Nintedanib can be increased when it is combined with Raloxifene.
RanitidineThe serum concentration of Nintedanib can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Nintedanib can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Nintedanib can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Nintedanib can be increased when it is combined with Regorafenib.
RepaglinideThe serum concentration of Nintedanib can be increased when it is combined with Repaglinide.
ReserpineThe serum concentration of Nintedanib can be decreased when it is combined with Reserpine.
ResveratrolThe serum concentration of Nintedanib can be increased when it is combined with Resveratrol.
ReviparinThe risk or severity of adverse effects can be increased when Reviparin is combined with Nintedanib.
RifabutinThe serum concentration of Nintedanib can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Nintedanib can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Nintedanib can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Nintedanib can be decreased when it is combined with Rifaximin.
RilpivirineThe serum concentration of Nintedanib can be decreased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Nintedanib can be increased when it is combined with Risperidone.
RitonavirThe serum concentration of Nintedanib can be increased when it is combined with Ritonavir.
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Nintedanib.
RivastigmineThe serum concentration of Nintedanib can be increased when it is combined with Rivastigmine.
RofecoxibThe serum concentration of Nintedanib can be decreased when it is combined with Rofecoxib.
RolapitantThe serum concentration of Nintedanib can be increased when it is combined with Rolapitant.
RolitetracyclineThe serum concentration of Nintedanib can be increased when it is combined with Rolitetracycline.
RosuvastatinThe serum concentration of Nintedanib can be increased when it is combined with Rosuvastatin.
RoxithromycinThe serum concentration of Nintedanib can be increased when it is combined with Roxithromycin.
RufinamideThe serum concentration of Nintedanib can be decreased when it is combined with Rufinamide.
RutinThe serum concentration of Nintedanib can be increased when it is combined with Rutin.
SalbutamolThe serum concentration of Nintedanib can be increased when it is combined with Salbutamol.
SaquinavirThe serum concentration of Nintedanib can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Nintedanib can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Nintedanib can be increased when it is combined with Selegiline.
SeratrodastThe serum concentration of Nintedanib can be decreased when it is combined with Seratrodast.
SertralineThe serum concentration of Nintedanib can be increased when it is combined with Sertraline.
SildenafilThe serum concentration of Nintedanib can be increased when it is combined with Sildenafil.
SimeprevirThe serum concentration of Nintedanib can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Nintedanib can be decreased when it is combined with Simvastatin.
SirolimusThe serum concentration of Nintedanib can be decreased when it is combined with Sirolimus.
SitaxentanThe serum concentration of Nintedanib can be increased when it is combined with Sitaxentan.
SorafenibThe serum concentration of Nintedanib can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Nintedanib can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Nintedanib can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Nintedanib can be increased when it is combined with Staurosporine.
StreptozocinThe serum concentration of Nintedanib can be decreased when it is combined with Streptozocin.
SulfamethoxazoleThe serum concentration of Nintedanib can be increased when it is combined with Sulfamethoxazole.
SulfanilamideThe serum concentration of Nintedanib can be increased when it is combined with Sulfanilamide.
SulfinpyrazoneThe serum concentration of Nintedanib can be decreased when it is combined with Sulfinpyrazone.
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Nintedanib.
SumatriptanThe serum concentration of Nintedanib can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Nintedanib can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Nintedanib can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Nintedanib can be decreased when it is combined with Tacrolimus.
TadalafilThe serum concentration of Nintedanib can be increased when it is combined with Tadalafil.
TamoxifenThe serum concentration of Nintedanib can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Nintedanib can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Nintedanib can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Nintedanib can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Nintedanib can be increased when it is combined with Telmisartan.
TemozolomideThe serum concentration of Nintedanib can be decreased when it is combined with Temozolomide.
TemsirolimusThe serum concentration of Nintedanib can be increased when it is combined with Temsirolimus.
TeniposideThe serum concentration of Nintedanib can be increased when it is combined with Teniposide.
TerazosinThe serum concentration of Nintedanib can be increased when it is combined with Terazosin.
TerbinafineThe serum concentration of Nintedanib can be decreased when it is combined with Terbinafine.
TerfenadineThe serum concentration of Nintedanib can be decreased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Nintedanib can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Nintedanib can be decreased when it is combined with Testosterone.
TetracyclineThe serum concentration of Nintedanib can be increased when it is combined with Tetracycline.
ThiopentalThe serum concentration of Nintedanib can be increased when it is combined with Thiopental.
TicagrelorThe serum concentration of Nintedanib can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Nintedanib can be increased when it is combined with Ticlopidine.
TioconazoleThe serum concentration of Nintedanib can be increased when it is combined with Tioconazole.
TipranavirThe serum concentration of Nintedanib can be increased when it is combined with Tipranavir.
TofisopamThe serum concentration of Nintedanib can be increased when it is combined with Tofisopam.
TolvaptanThe serum concentration of Nintedanib can be increased when it is combined with Tolvaptan.
TopiramateThe serum concentration of Nintedanib can be decreased when it is combined with Topiramate.
TopotecanThe serum concentration of Nintedanib can be decreased when it is combined with Topotecan.
TramadolThe serum concentration of Nintedanib can be increased when it is combined with Tramadol.
TrametinibThe serum concentration of Nintedanib can be decreased when it is combined with Trametinib.
TranylcypromineThe serum concentration of Nintedanib can be increased when it is combined with Tranylcypromine.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Nintedanib.
TrazodoneThe serum concentration of Nintedanib can be decreased when it is combined with Trazodone.
TrifluoperazineThe serum concentration of Nintedanib can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Nintedanib can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Nintedanib can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Nintedanib can be increased when it is combined with Trimipramine.
TroglitazoneThe serum concentration of Nintedanib can be decreased when it is combined with Troglitazone.
TroleandomycinThe serum concentration of Nintedanib can be increased when it is combined with Troleandomycin.
Valproic AcidThe serum concentration of Nintedanib can be increased when it is combined with Valproic Acid.
VemurafenibThe serum concentration of Nintedanib can be decreased when it is combined with Vemurafenib.
VenlafaxineThe serum concentration of Nintedanib can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Nintedanib can be decreased when it is combined with Verapamil.
VinblastineThe serum concentration of Nintedanib can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Nintedanib can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Nintedanib can be increased when it is combined with Vinorelbine.
VoriconazoleThe serum concentration of Nintedanib can be increased when it is combined with Voriconazole.
WarfarinThe risk or severity of adverse effects can be increased when Warfarin is combined with Nintedanib.
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Nintedanib.
ZafirlukastThe serum concentration of Nintedanib can be increased when it is combined with Zafirlukast.
ZimelidineThe serum concentration of Nintedanib can be increased when it is combined with Zimelidine.
ZiprasidoneThe serum concentration of Nintedanib can be increased when it is combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Vegf-b-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation ...
Gene Name:
FLT1
Uniprot ID:
P17948
Molecular Weight:
150767.185 Da
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domai...
Gene Name:
KDR
Uniprot ID:
P35968
Molecular Weight:
151525.555 Da
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced pr...
Gene Name:
FLT4
Uniprot ID:
P35916
Molecular Weight:
152755.94 Da
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
4. Platelet derived growth factor receptor alpha
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
5. Platelet derived growth factor receptor beta
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (...
Gene Name:
FGFR1
Uniprot ID:
P11362
Molecular Weight:
91866.935 Da
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an...
Gene Name:
FGFR2
Uniprot ID:
P21802
Molecular Weight:
92024.29 Da
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineraliz...
Gene Name:
FGFR3
Uniprot ID:
P22607
Molecular Weight:
87708.905 Da
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
Inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or...
Gene Name:
FLT3
Uniprot ID:
P36888
Molecular Weight:
112902.51 Da
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
Inhibitor
General Function:
Sh2 domain binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antig...
Gene Name:
LCK
Uniprot ID:
P06239
Molecular Weight:
58000.15 Da
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
Inhibitor
General Function:
Receptor signaling protein tyrosine kinase activity
Specific Function:
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending ...
Gene Name:
LYN
Uniprot ID:
P07948
Molecular Weight:
58573.595 Da
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
Inhibitor
General Function:
Sh3/sh2 adaptor activity
Specific Function:
Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including...
Gene Name:
SRC
Uniprot ID:
P12931
Molecular Weight:
59834.295 Da
References
  1. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. [PubMed:18559524 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on June 24, 2015 05:32 / Updated on October 01, 2016 02:24